{"id":"W2142830692","doi":"10.1056/nejmoa1501352","title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2590,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Canadian VIGOUR Centre; St. Michael's Hospital; University of Alberta","funders":"South Australian Health and Medical Research Institute","keywords":"Sitagliptin; Medicine; Semaglutide; Placebo; Hazard ratio; Sitagliptin Phosphate; Myocardial infarction; Internal medicine; Glycated hemoglobin; Alogliptin; Glycemic; Type 2 diabetes; Relative risk; Confidence interval; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Heart failure; Endocrinology; Insulin; Liraglutide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}